Search results
Results from the WOW.Com Content Network
The treatment of chronic liver disease depends on the cause. Specific conditions may be treated with medications including corticosteroids, interferon, antivirals, bile acids or other drugs. Supportive therapy for complications of cirrhosis include diuretics, albumin, vitamin K, blood products, antibiotics and nutritional therapy.
All cause mortality in MASH is 25.5 per 1000 person years with a liver specific mortality of 11.7 per 1000 person years. The most common cause of death in those with MASH is cardiovascular disease. [3] MASH is associated with a 1.7 times overall mortality, 15 times liver specific mortality and 12 times risk of liver cancer as compared to MASLD. [3]
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, chronic liver failure or chronic hepatic failure and end-stage liver disease, is a condition of the liver in which the normal functioning tissue, or parenchyma, is replaced with scar tissue and regenerative nodules as a result of chronic liver disease.
Non-alcoholic fatty liver disease is a spectrum of disease associated with obesity and metabolic syndrome. [9] Hereditary diseases that cause damage to the liver include hemochromatosis, [10] involving accumulation of iron in the body, and Wilson's disease.
Other causes include: infiltrative liver diseases, granulomatous liver disease, abscess, amyloidosis of the liver and peripheral arterial disease. Mild elevation of ALP can be seen in liver cirrhosis, hepatitis, and congestive cardiac failure. Transient hyperphosphataemia is a benign condition in infants, and can reach normal level in 4 months.
Portal vein thrombosis (PVT) is a vascular disease of the liver that occurs when a blood clot occurs in the hepatic portal vein, which can lead to increased pressure in the portal vein system and reduced blood supply to the liver. The mortality rate is approximately 1 in 10. [1]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Non-alcoholic fatty liver disease prevalence in 2019. MASLD incidence is rapidly rising, along with obesity and diabetes, and has become the most common cause of liver disease in developed countries, for adults, teenagers, and children. [24] [25] The percentage of people with MASLD ranges from 9 to 36.9% in different parts of the world.